- Home
- VSTM vs DBVT Comparison
VSTM vs DBVT Comparison
Compare VSTM & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- DBVT
- Stock Information
- Founded
- VSTM 2010
- DBVT 2002
- Country
- VSTM United States
- DBVT France
- Employees
- VSTM N/A
- DBVT N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VSTM Health Care
- DBVT Health Care
- Exchange
- VSTM Nasdaq
- DBVT Nasdaq
- Market Cap
- VSTM 493.6M
- DBVT 464.0M
- IPO Year
- VSTM 2012
- DBVT N/A
- Fundamental
- Price
- VSTM $8.85
- DBVT $14.12
- Analyst Decision
- VSTM Strong Buy
- DBVT Buy
- Analyst Count
- VSTM 9
- DBVT 4
- Target Price
- VSTM $13.38
- DBVT $14.81
- AVG Volume (30 Days)
- VSTM 2.2M
- DBVT 203.8K
- Earning Date
- VSTM 11-04-2025
- DBVT 10-28-2025
- Dividend Yield
- VSTM N/A
- DBVT N/A
- EPS Growth
- VSTM N/A
- DBVT N/A
- EPS
- VSTM N/A
- DBVT N/A
- Revenue
- VSTM $2,137,000.00
- DBVT $3,800,000.00
- Revenue This Year
- VSTM $79.32
- DBVT $1,743.46
- Revenue Next Year
- VSTM $413.52
- DBVT $1,044.34
- P/E Ratio
- VSTM N/A
- DBVT N/A
- Revenue Growth
- VSTM N/A
- DBVT N/A
- 52 Week Low
- VSTM $3.19
- DBVT $2.21
- 52 Week High
- VSTM $11.25
- DBVT $18.00
- Technical
- Relative Strength Index (RSI)
- VSTM 51.64
- DBVT 50.21
- Support Level
- VSTM $7.60
- DBVT $14.85
- Resistance Level
- VSTM $9.16
- DBVT $16.95
- Average True Range (ATR)
- VSTM 0.66
- DBVT 1.04
- MACD
- VSTM -0.02
- DBVT -0.30
- Stochastic Oscillator
- VSTM 61.99
- DBVT 0.00
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.